NCT06931288 is a NA clinical trial of Blood pressure monitor in Atrial Fibrillation (AF), sponsored by Shanghai Jiao Tong University School of Medicine.

Who is sponsoring NCT06931288?

NCT06931288 is sponsored by Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT06931288?

Interventions in NCT06931288: Blood pressure monitor, Single-lead ECG.

What condition does NCT06931288 study?

NCT06931288 studies Atrial Fibrillation (AF).

Is NCT06931288 still recruiting?

NCT06931288 is currently not yet recruiting. Last updated 17 April 2025.

Last reviewed 2025-04-17 · How we verify

NCT06931288

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Electronic Blood Pressure Monitor for Atrial Fibrillation Detection

Not yet recruiting NA Last updated 17 April 2025

What this trial tests

NA trial testing Blood pressure monitor in Atrial Fibrillation (AF) in 20,000 participants. Not yet recruiting.

Timeline

6 May 2025

Primary endpoint
31 July 2026

31 July 2026

Quick facts

Lead sponsor	Shanghai Jiao Tong University School of Medicine
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	screening
Enrollment	20,000
Start date	6 May 2025
Primary completion	31 July 2026
Estimated completion	31 July 2026
Sites	1 location across China

Drugs / interventions tested

Blood pressure monitor
Single-lead ECG

Conditions studied

Atrial Fibrillation (AF) — all drugs for Atrial Fibrillation (AF) →

Sponsor

Shanghai Jiao Tong University School of Medicine

Who can join

Adults 60 to 125, any sex, with Atrial Fibrillation (AF). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study name: Study on the Effectiveness of Atrial Fibrillation Screening Using Electronic Blood Pressure Monitor with Atrial Fibrillation Detection Function Objective: This study compares an electronic blood pressure monitor (BP77A1T, Omron Healthcare, Kyoto, Japan) with single-lead electrocardiography for atrial fibrillation detection in an elderly Chinese population. Study design: This study is a cluster-randomized and controlled trial. Study population: Men and women aged over 60 years meeting the inclusion/exclusion criteria. Randomization and treatment: Eligible centers as clusters will be randomly assigned to either the single-lead electrocardiography group or the electronic blood pressure monitor group for atrial fibrillation detection. Sample size: About 50 centers, at least 20,000 participants. Timeline: Participants enrollment are expected to be performed from May 2025 to July 2026. Organization: The Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai, China.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood pressure monitor

Trials testing the same drug.

NCT05388578 — The Stroke Box: a Patient-centered eHealth Approach for Improving Post-stroke Care. · unknown

Other recruiting trials for Atrial Fibrillation (AF)

Currently open trials in the same condition.

NCT07298473 — Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sp · NA · recruiting
NCT07442175 — Blood Pressure Monitor (TH-75) Atrial Fibrillation Detection Function Clinical Trial · recruiting
NCT07389434 — Feasibility, Safety, Cost-effectiveness, and Environmental Impact of Reprocessed Ablation Catheters in PVI · NA · recruiting
NCT07250529 — Left Bundle Branch Pacing vs Right Ventricular Pacing on AHRE Burden in Patients With Preserved LVEF · NA · recruiting
NCT07358611 — Non-invasive Mapping-Guided Atrial Fibrillation Ablation · NA · recruiting

Other Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting
NCT07528079 — Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors · NA · enrolling by invitation
NCT07535710 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-ce · Phase 1, PHASE2 · not yet recruiting
NCT07535762 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T · Phase 2 · not yet recruiting
NCT07350057 — A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graf · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06931288 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University School of Medicine
Last refreshed: 17 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06931288.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing